ID
34016
Description
Study ID: 103974 (primary study) Clinical Study ID: 103974 Study Title: Demonstrate non-inferiority of Men-C immune response of Hib-MenC with Infanrix™-IPV versus a licensed Men-C vaccine with Pediacel™ when given at 2, 3, 4 months and the immunogenicity of Hib-MenC when given as a booster dose at 12-15 months Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00258700 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine Trade Name: BIO HIB-MENC-TT; Menitorix Study Indication: Haemophilus influenzae type b; Neisseria Meningitidis
Keywords
Versions (1)
- 1/11/19 1/11/19 -
Copyright Holder
GSK group of companies
Uploaded on
January 11, 2019
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Primary & Booster Immunogenicity of Hib-MenC vs a Licensed Men-C Vaccine - 103974
Visit 6: Eligibility Check, Laboratory Test
- StudyEvent: ODM
Description
Check for Study Continuation
Description
Did the subject return for Visit 6?
Data type
boolean
Description
If No, please tick ONE most appropriate reason
Data type
text
Description
If Other, please specify
Data type
text
Description
If SAE, record the SAE number
Data type
integer
Description
If non-SAE, please record the AE number
Data type
integer
Description
Please tick who took the decision
Data type
text
Description
Elimination Criteria During The Study
Description
If any of the criteria become applicable during the study, it will not require withdrawal of the subject from the study but may determine a subject's evaluability in the according-to-protocol (ATP) analysis.
Data type
text
Description
1. Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) during the study period
Data type
text
Description
2. Chronic administration (defined as more than 14 days) or immunodepressants or other imminodefying drugs during the study period.
Data type
text
Description
3. Administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of vaccine(s) and ending 30 days after
Data type
text
Description
4. Administration of immunoglobulins and/or any blood products during the study period
Data type
text
Description
Laboratory Tests - Blood
Similar models
Visit 6: Eligibility Check, Laboratory Test
- StudyEvent: ODM
No comments